JP2014118361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014118361A5 JP2014118361A5 JP2012272828A JP2012272828A JP2014118361A5 JP 2014118361 A5 JP2014118361 A5 JP 2014118361A5 JP 2012272828 A JP2012272828 A JP 2012272828A JP 2012272828 A JP2012272828 A JP 2012272828A JP 2014118361 A5 JP2014118361 A5 JP 2014118361A5
- Authority
- JP
- Japan
- Prior art keywords
- fsp
- vaccination
- tumors
- msi
- endometrium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 1
- 210000004696 Endometrium Anatomy 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
Description
要約すると、
（ａ）フレームシフトペプチド（ＦＳＰ）はＭＳＩ特異的であり、ＭＳＩ腫瘍の病因に直接起因し、
（ｂ）臨床的に関連する副作用がないことが期待され、
（ｃ）ＦＳＰの組合せ（複数）がＭＳＩを有する全ての腫瘍を標的とすることが予測され、
（ｄ）ＦＳＰワクチン接種が、結腸がんの１５％、並びに子宮内膜、胃、小腸及び他の臓器の腫瘍の治療のために設計されており、
（ｅ）分子腫瘍分析により、ＦＳＰワクチン接種（標的療法）の恩恵を受けることができる患者を特定することができ、
（ｆ）ＦＳＰワクチン接種を高リスク群における予防ワクチン接種として使用することができる。
In summary,
(A) Frameshift peptide (FSP) is MSI specific and directly results from the pathogenesis of MSI tumors,
(B) Expected to have no clinically relevant side effects,
(C) FSP combination (s) are predicted to target all tumors with MSI,
(D) FSP vaccination is designed for the treatment of 15% of colon cancer and tumors of the endometrium, stomach, small intestine and other organs;
(E) Molecular tumor analysis can identify patients who can benefit from FSP vaccination (targeted therapy),
(F) FSP vaccination can be used as preventive vaccination in high risk groups.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012272828A JP5890769B2 (en) | 2012-12-13 | 2012-12-13 | MSI-specific frameshift peptides (FSP) for cancer prevention and treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012272828A JP5890769B2 (en) | 2012-12-13 | 2012-12-13 | MSI-specific frameshift peptides (FSP) for cancer prevention and treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015149569A Division JP2016028025A (en) | 2015-07-29 | 2015-07-29 | Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014118361A JP2014118361A (en) | 2014-06-30 |
| JP2014118361A5 true JP2014118361A5 (en) | 2015-10-15 |
| JP5890769B2 JP5890769B2 (en) | 2016-03-22 |
Family
ID=51173521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012272828A Active JP5890769B2 (en) | 2012-12-13 | 2012-12-13 | MSI-specific frameshift peptides (FSP) for cancer prevention and treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5890769B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020522477A (en) * | 2017-06-02 | 2020-07-30 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | General purpose cancer vaccine and methods of making and using same |
| CN111328420B (en) * | 2017-07-12 | 2023-07-25 | Nouscom股份公司 | Universal vaccine based on consensus tumor neoantigen for prevention and treatment of microsatellite instability (MSI) cancers |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO315238B1 (en) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptides derived from reading frame shift mutations in the TBF <beta> II or BAX gene, and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids, and virus vector-encompassing such nucleic acid |
| WO2003087162A2 (en) * | 2002-04-18 | 2003-10-23 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
-
2012
- 2012-12-13 JP JP2012272828A patent/JP5890769B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118813T1 (en) | PHARMACEUTICAL COMPOSITIONS OF TRAMADOL AND COXYL-CYLINDERS | |
| JP2017006120A5 (en) | ||
| BR212016030926U2 (en) | target conjugates and particles and formulations thereof | |
| BR112012024590A2 (en) | methods of enhancing drug release and efficacy of therapeutic agents | |
| EA201491299A1 (en) | CARBAMATIC CONNECTIONS, THEIR PRODUCTION AND APPLICATION | |
| IN2015DN00376A (en) | ||
| JP2016528162A5 (en) | ||
| JP2014512354A5 (en) | ||
| WO2012142529A3 (en) | Clonal strains of attenuated vaccinia viruses and methods of use thereof | |
| BR112014019459A8 (en) | DCIM-BINDING PROTEINS AND USES THEREOF | |
| MX360179B (en) | Compositions and methods for parkinson's disease treatment by bdnf-flag gene transfer through neurotensin polyplex to nigral dopamine neurons. | |
| BR112012020373A2 (en) | isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tata419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent | |
| EP3818991A3 (en) | Compositions and methods for treating diseases | |
| TR201909355T4 (en) | Proton binding polymers for oral administration. | |
| MX2023010328A (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof. | |
| NZ700872A (en) | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma | |
| EA201690004A1 (en) | ANTIBODIES AGAINST LAMP1 AND CONJUGATES ANTIBODIES AND MEDICINES AND THEIR APPLICATION | |
| JP2016519107A5 (en) | ||
| JP2016535794A5 (en) | Rapidly disintegrating solid dosage form | |
| BR112012026224A2 (en) | methods for treating alzheimer's disease and for evaluating the effectiveness of a | |
| JP2014118361A5 (en) | ||
| RU2016108808A (en) | THERAPEUTIC USE OF VEGF-C AND CCBE1 | |
| JP2014526564A5 (en) | ||
| CY1116088T1 (en) | DANGEROUS HEALTHCARE AND USE FOR THERAPY AND PREVENTION OF HEART DISEASES | |
| RU2014101462A (en) | CANCER ANTIGEN |